

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

and

LUPIN LTD. and LUPIN PHARMACEUTICALS, INC.
Petitioners,

v.

HORIZON THERAPEUTICS, INC.,
Patent Owner.

Case IPR2015-01117¹
Patent 8,642,012

PETITIONERS' REQUEST FOR ORAL HEARING

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

¹ Case IPR2015-00283, instituted on a petition filed by Lupin Ltd. and Lupin Pharmaceuticals, Inc., has been joined with this proceeding.

IPR2015-01117
Patent No. 8,642,012
Petitioners' Request for Oral Hearing

Pursuant to 37 C.F.R. § 42.70(a), Petitioners Par Pharmaceutical, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc. (collectively, "Petitioners") submit this Request for Oral Hearing on all of the instituted grounds of unpatentability of claims 1-12 of U.S. Patent No. 8,642,012 under 35 U.S.C. § 103. The Board has already scheduled Oral Hearing for July 26, 2016. *See* Paper 14, at 6.

Petitioners respectfully request that the Board conduct a consolidated hearing in *Inter Partes* Review Nos. 2015-01117 and -01127, both of which are scheduled for hearing on July 26, 2016, before the same Board Panel, for convenience and efficiency. Petitioners further request that the Board provide Petitioners seventy-five minutes (75 minutes) to present their arguments in the two cases (i.e., 75 minutes cumulative total time for the two cases, including time to be reserved for rebuttal), and provide Patent Owner with seventy-five minutes (75 minutes) to present responsive arguments. Petitioners also request the ability to use audio/visual equipment to display demonstrative exhibits, including the use of a projector and screen for a PowerPoint presentation. Because of the number of anticipated attendees at the hearing, Petitioners request that the largest hearing room available be reserved for the hearing.

IPR2015-01117
Patent No. 8,642,012
Petitioners' Request for Oral Hearing

Date: June 16, 2016
Axinn, Veltrop & Harkrider LLP
950 F Street, N.W.
Washington, DC 20004
Tel: (202) 912-4700

Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
Tel: (212) 813-8800

Respectfully Submitted,



David H. Silverstein
Registration No. 61,948
Attorney for Petitioner
Par Pharmaceutical, Inc.

/Elizabeth J. Holland/
Elizabeth J. Holland
Registration No. 47,657
Attorney for Petitioners
Lupin Ltd. and Lupin
Pharmaceuticals, Inc.

CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))

The undersigned hereby certifies that the above-captioned “Petitioners’ Request for Oral Hearing” was served in its entirety on June 16, 2016 through the Patent Review Processing System, and additionally upon the following parties via

Electronic Mail:

For Patent Owner:

Lauren Stevens:
lstevens@horizonpharma.com
Matthew C. Phillips:
matthew.phillips@renaissanceiplaw.com
Dennis Bennett:
dennisbennett@globalpatentgroup.com


Robert Green:
rgreen@greengriffith.com
Emer Simic: esimic@greengriffith.com
Jessica Tyrus: jtyrus@greengriffith.com

Date: June 16, 2016
Axinn, Veltrop & Harkrider LLP
950 F Street, N.W.
Washington, DC 20004
Tel: (202) 912-4700

For Petitioner Lupin:

Elizabeth J. Holland
Cynthia Lambert Hardman
GOODWIN PROCTER LLP
eholland@goodwinproctor.com
chardman@goodwinproctor.com

Respectfully Submitted,



David H. Silverstein
Registration No. 61,948
Attorney for Petitioner
Par Pharmaceutical, Inc.